Table 3. Cox Regression Analysis of Time... | American Society of Hematology

Table 3.

Cox Regression Analysis of Time to Event Data

Event	Intent to Treat
	GVHD Prophylaxis		Relative Risk			Actual Treatment
	(no. of events)		Estimate	95% CI	P Value	GVHD Prophylaxis		Relative Risk
	CSP	CSP + MP				(no. of events)		Estimate	95% CI	P Value
	(n = 60)	(n = 62)				CSP	CSP + MP
						(n = 52)	(n = 55)
Acute GVHD
Grades I-IV	49	41	0.49	(0.32,0.75)	.001	42	39	0.49	(0.31,0.77)	.002
Grades II-IV	44	37	0.57	(0.37,0.89)	.01	39	35	0.55	(0.35,0.88)	.01
Grades III-IV	24	21	0.72	(0.40,1.30)	.28	22	20	0.70	(0.38,1.28)	.24
Chronic GVHD
Original treatment assignment	12	25	2.33	(1.16,4.71)	.02	12	23	1.78	(0.88,3.63)	.11
Censored at steroid treatment	1	12	6.28	(0.81,48.4)	.08	1	10	3.70	(0.47,29.1)	.21
All deaths	43	43	0.85	(0.56,1.30)	.45
Relapse	17	13	0.55	(0.27,1.13)	.10
Nonrelapse mortality	31	31	0.77	(0.47,1.27)	.31
Relapse-free survival	12	18	0.69	(0.46,1.04)	.07
Infection
First infection	38	36	0.79	(0.50,1.25)	.32	33	31	0.68	(0.42,1.12)	.13
All infections	56	61	0.97	(0.68,1.40)	.88
First bacterial infection	29	32	0.95	(0.57,1.57)	.84
All bacterial infections	40	40	0.89	(0.58,1.38)	.61
First fungal infection	11	14	1.17	(0.53,2.59)	.69
All fungal infections	12	16	1.21	(0.57,2.56)	.62
First invasive infection^3-150	25	26	0.90	(0.52,1.56)	.71
All invasive infections^3-150	27	34	1.13	(0.68,1.87)	.64

Event	Intent to Treat
	GVHD Prophylaxis		Relative Risk			Actual Treatment
	(no. of events)		Estimate	95% CI	P Value	GVHD Prophylaxis		Relative Risk
	CSP	CSP + MP				(no. of events)		Estimate	95% CI	P Value
	(n = 60)	(n = 62)				CSP	CSP + MP
						(n = 52)	(n = 55)
Acute GVHD
Grades I-IV	49	41	0.49	(0.32,0.75)	.001	42	39	0.49	(0.31,0.77)	.002
Grades II-IV	44	37	0.57	(0.37,0.89)	.01	39	35	0.55	(0.35,0.88)	.01
Grades III-IV	24	21	0.72	(0.40,1.30)	.28	22	20	0.70	(0.38,1.28)	.24
Chronic GVHD
Original treatment assignment	12	25	2.33	(1.16,4.71)	.02	12	23	1.78	(0.88,3.63)	.11
Censored at steroid treatment	1	12	6.28	(0.81,48.4)	.08	1	10	3.70	(0.47,29.1)	.21
All deaths	43	43	0.85	(0.56,1.30)	.45
Relapse	17	13	0.55	(0.27,1.13)	.10
Nonrelapse mortality	31	31	0.77	(0.47,1.27)	.31
Relapse-free survival	12	18	0.69	(0.46,1.04)	.07
Infection
First infection	38	36	0.79	(0.50,1.25)	.32	33	31	0.68	(0.42,1.12)	.13
All infections	56	61	0.97	(0.68,1.40)	.88
First bacterial infection	29	32	0.95	(0.57,1.57)	.84
All bacterial infections	40	40	0.89	(0.58,1.38)	.61
First fungal infection	11	14	1.17	(0.53,2.59)	.69
All fungal infections	12	16	1.21	(0.57,2.56)	.62
First invasive infection^3-150	25	26	0.90	(0.52,1.56)	.71
All invasive infections^3-150	27	34	1.13	(0.68,1.87)	.64

Includes gram-negative, fungal, and polymicrobial infections.